In a regulatory filing, Phathom Pharmaceuticals (PHAT) disclosed that its director bought 10K shares of common stock on March 13th in a total transaction size of $44.2K. Shares are up 6.6% afterhours at $5.16.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges
- Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs
- Phathom Pharmaceuticals price target lowered to $18 from $28 at Guggenheim
- Phathom Pharmaceuticals price target lowered to $19 from $27 at Craig-Hallum
- Phathom Pharmaceuticals: Strategic Positioning and Growth Potential in GERD Market Drives Buy Rating